{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06286475",
            "orgStudyIdInfo": {
                "id": "VGCS-50635-003"
            },
            "organization": {
                "fullName": "Verge Genomics",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of VRG50635 in Healthy Volunteers",
            "officialTitle": "A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of VRG50635 in Healthy Volunteers",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-of-in-healthy-volunteers"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-02-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-21",
            "studyFirstSubmitQcDate": "2024-02-22",
            "studyFirstPostDateStruct": {
                "date": "2024-02-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-27",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Verge Genomics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary objectives of this study are to investigate the safety and tolerability of VRG50635 and to determine how VRG50635 is absorbed by the body."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteers"
            ],
            "keywords": [
                "Amyotrophic lateral sclerosis",
                "ALS"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "This is a 2-part study that includes both an open-label (Part 1) and a double-blind, placebo-controlled (Part 2) design. In Part 1, participants will be randomly assigned to receive open-label VRG50635 in 1 of 2 treatment sequences. In Part 2, participants will receive VRG50635 or placebo in a double-blind manner.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1: VRG50635 Sequence A, B, C",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive a single dose of VRG50635 in each of 3 treatment periods separated by 14-day washout periods.",
                    "interventionNames": [
                        "Drug: VRG50635"
                    ]
                },
                {
                    "label": "Part 1: VRG50635 Sequence B, A, C",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive a single dose of VRG50635 in each of 3 treatment periods separated by 14-day washout periods.",
                    "interventionNames": [
                        "Drug: VRG50635"
                    ]
                },
                {
                    "label": "Part 2: Cohort 1 VRG50635",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive VRG50635 (Dose X) for 14 consecutive days.",
                    "interventionNames": [
                        "Drug: VRG50635"
                    ]
                },
                {
                    "label": "Part 2: Cohort 1 Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive VRG50635-matching placebo for 14 consecutive days.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Part 2: Cohort 2 VRG50635",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive VRG50635 (Dose Y) for 14 consecutive days.",
                    "interventionNames": [
                        "Drug: VRG50635"
                    ]
                },
                {
                    "label": "Part 2: Cohort 2 Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will receive VRG50635-matching placebo for 14 consecutive days.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "VRG50635",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part 1: VRG50635 Sequence A, B, C",
                        "Part 1: VRG50635 Sequence B, A, C",
                        "Part 2: Cohort 1 VRG50635",
                        "Part 2: Cohort 2 VRG50635"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Specified dose on specified days",
                    "armGroupLabels": [
                        "Part 2: Cohort 1 Placebo",
                        "Part 2: Cohort 2 Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants with Adverse Events",
                    "timeFrame": "Up to Day 30"
                },
                {
                    "measure": "Area Under the Concentration-time Curve from Time 0 Extrapolated to Infinity (AUCinf)",
                    "timeFrame": "Up to Day 16"
                },
                {
                    "measure": "Area Under the Concentration-time Curve from Time 0 to the Last Measurable Concentration (AUClast)",
                    "timeFrame": "Up to Day 16"
                },
                {
                    "measure": "Area Under the Concentration-time Curve from Time 0 to 24 Hours Post-dose (AUC0-24)",
                    "timeFrame": "Up to Day 16"
                },
                {
                    "measure": "Area Under the Concentration-time Curve Between Consecutive Doses (AUCtau)",
                    "timeFrame": "Up to Day 16"
                },
                {
                    "measure": "Maximum Observed Concentration (Cmax)",
                    "timeFrame": "Up to Day 16"
                },
                {
                    "measure": "Half-life (t1/2)",
                    "timeFrame": "Up to Day 16"
                },
                {
                    "measure": "Time of Maximal Plasma Concentration (tmax)",
                    "timeFrame": "Up to Day 16"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Must have a body mass index \u2265 18.5 and \u2264 32 kilogram per square meter (kg/m2) and weigh \u2265 50 kg.\n* Participants of childbearing potential are eligible to participate if they are not pregnant or breastfeeding and agree to use 1 highly effective and 1 barrier method of contraception, if sexually active, for the duration of the study through 90 days after the last study drug administration. Participants must not donate eggs for the duration of study through 90 days after the last dose of study drug.\n* Participants capable of producing sperm must agree that they will use 1 barrier method of contraception and that their partners of childbearing potential will use 1 highly effective method of contraception for the duration of the study through 90 days after the last study drug administration. Participants must not donate sperm for the duration of study through 90 days after the last dose of study drug.\n\nExclusion Criteria:\n\n* Have a history of clinically significant hematologic, renal, neurologic, pancreatic, gastrointestinal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, immunological, allergic disease, or other major disorders, as determined by the principal investigator (PI).\n* Have any surgical or medical condition that could possibly affect drug absorption (including inflammatory bowel disease, history of gastrectomy, cholecystectomy, or other gastrointestinal tract surgery except appendectomy).\n* Have a current significant medical or psychiatric condition, as determined by the PI.\n\nOther protocol-defined criteria apply.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "19 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Verge Genomics",
                    "role": "CONTACT",
                    "phone": "Please Email",
                    "email": "clinicaltrials@vergegenomics.com"
                }
            ],
            "locations": [
                {
                    "facility": "Site 001",
                    "status": "RECRUITING",
                    "city": "Lincoln",
                    "state": "Nebraska",
                    "zip": "68502",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.8,
                        "lon": -96.66696
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M18879",
                    "name": "Motor Neuron Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M4024",
                    "name": "Amyotrophic Lateral Sclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "M15415",
                    "name": "Sclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "T349",
                    "name": "Amyotrophic Lateral Sclerosis",
                    "relevance": "LOW"
                },
                {
                    "id": "T4699",
                    "name": "Primary Lateral Sclerosis",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}